Background The rapid process of research and development and lack of follow-up time post-
vaccination aroused great public concern about the safety profile of COVID-19 vaccine …

Since the beginning of vaccination programs against COVID-19 in different countries,
several populations such as patients with specific immunological conditions have been …

Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown
to be well tolerated with a good safety profile in individuals aged 18 years and older in …

Objective To estimate the effectiveness of the inactivated whole virus vaccine, CoronaVac
(Sinovac Biotech), against symptomatic covid-19 in the elderly population of São Paulo …

Background A vaccine against SARS-CoV-2 for children and adolescents will play an
important role in curbing the COVID-19 pandemic. Here we aimed to assess the safety …

CoronaVac, an inactivated SARS-CoV-2 vaccine, has been approved for emergency use in
several countries. However, its immunogenicity in immunocompromised individuals has not …

Background and objective Few head‐to‐head evaluations of immune responses to different
vaccines have been reported. Methods Surrogate virus neutralization test (sVNT) antibody …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant,
Gamma, emerged in the city of Manaus in late 2020 during a large resurgence of …

Background Mutations accrued by SARS-CoV-2 lineage P. 1—first detected in Brazil in early
January, 2021—include amino acid changes in the receptor-binding domain of the viral …

Background Although the serological antibody responses induced by SARS-CoV-2 vaccines
are well characterized, little is known about their ability to elicit mucosal immunity. Objectives …